Pharminent

Reversal agents could unclot the NOAC market

Boehringer bolstered evidence for its antidote Praxbind, but the lack of other reversal agents for new oral anticoagulants has limited overall market growth.  http://www.biopharmadive.com/news/reversal-agents-could-unclot-the-noac-market/430527/

Filed under: Cardiovascular